The next hurdle pharma faces as it endeavors to limit the cost and time associated with its drug development failures is the headache of predictive efficacy. Emergent diagnostics/research tools companies are lining up for the opportunity to help, offering diversity both in approaches and in therapeutic areas.
In the 1980s, the majority of drugs that were tabled had poor pharmacokinetics, leading to a heavy pharma investment in...